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ABSTRACT: Smoking has been associated with several concerns in pregnancy including 
miscarriage, preterm delivery and stillbirth. Unfortunately, approximately 12% of the preg-
nant population continue to smoke cigarettes, suggesting a need for additional therapy be-
yond behavioural change. This paper reviews the literature on the use of nicotine replace-
ment therapy and bupropion (Zyban
®) in the pregnant human population, the pharmaco-
kinetics of nicotine in the pregnant woman, and current guidelines for smoking cessation for 
pregnant patients. There are currently four studies that have investigated the use of nicotine 
patch, three for nicotine gum, and registry and preliminary reports for bupropion. These 
studies did not show any adverse pregnancy outcomes with the use of pharmacological aid 
for smoking cessation. All the nicotine replacement therapy studies, with the exception of 
one randomized-controlled nicotine patch trial had small sample sizes and looked at short-
term use of drug in the third trimester. Two studies have examined the pharmacokinetics of 
nicotine in the pregnant woman. The results from these studies reveal greater nicotine me-
tabolism in pregnant individuals who continue to smoke during pregnancy. Current guide-
lines from several organizations uniformly recommend that Nicotine Replacement Therapy 
should be considered if non-pharmacological therapies have been unsuccessful. Bupropion 
is recommended in pregnancy if the benefits outweigh the risks. There is a need for further 
studies on the safety and effectiveness of Nicotine Replacement therapy and bupropion in 
pregnancy. However, considering the current research and guidelines, pharmacological ces-
sation aids should be considered if non-pharmacological therapies have not been effective. 
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INTRODUCTION 
 
Smoking during pregnancy is a serious terato-
genic concern. As early as the 1960s, research revealed 
a relationship between smoking and birth-weight [1]. 
Since then, numerous studies have found an association 
between smoking and an increased risk of several other 
adverse effects in pregnancy (Table 1). From this infor-
mation, the general population has been well informed 
that smoking during pregnancy is a risky behaviour. In 
a 1999 Annenberg Tobacco Survey given to 14- to 22-
year-olds in the US, 97% of non-smokers and 93% of 
smokers identified that smoking while pregnant can 
harm the baby [2]. This risk was more widely identified 
in the survey than deaths due to second-hand smoke 
and smoking causing lung damage after a few years. 
Despite the risk of smoking in pregnancy being well 
established in society, many pregnant women continue 
to smoke. The National Vital Statistics Report in the US 
reported that 12.2 percent of all women giving birth in 
2000 reported smoking during pregnancy [3]. With 4 
million births in the US for the same year, approxi-
mately 500,000 pregnancies were at risk because of 
maternal smoking. In the non-pregnant population, 
smoking cessation using nicotine replacement therapy 
(NRT), in the form of gum, patch, lozenge, nasal spray 
and inhaler have been found to be efficacious in in-
creasing quit rates [4-19]. As a result, NRT has been an 
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acceptable aid for smoking cessation in the general 
population.  
The drug manufacturers, on the other hand, have 
contraindicated the use of NRT in the pregnant popula-
tion. In a survey of six Boston, Massachusetts, obstetric 
clinics from 1996-1997, 42% of the obstetric providers 
did not discuss nicotine replacement therapy with any 
of their patients who continued to smoke cigarettes [20]. 
Given a hypothetical scenario about a 20-cigarettes-per-
day smoking pregnant woman motivated to quit using 
nicotine replacement therapy, 44% of the obstetric pro-
viders considered it usual practice to prescribe or rec-
ommend NRT [20]. However, if the safety of nicotine 
replacement therapy use in pregnancy was supported by 
“definitive evidence,” the number of practitioners rec-
ommending or prescribing this therapy increased to 
92%. This stresses the importance of understanding the 
safety and effectiveness of NRT use in pregnancy. Cur-
rently several studies have looked at the use of nicotine 
patch and nicotine gum in pregnant individuals. 
  
NICOTINE REPLACEMENT THERAPIES 
AND PREGNANCY 
 
Nicotine Patch 
Currently four studies have been conducted on 
the use of nicotine patch in pregnant women. A pro-
spective study by Wright et al (n=6) [21], monitored the 
mother and fetus during and after a six-hour application 
of 21-mg transdermal nicotine patch, following a day of 
smoking abstinence. Another prospective controlled 
study by Ogburn et al (n=21) [22], assessed maternal 
and fetal effects during a four-day application of 22-mg 
transdermal patch. Baseline measurements in normal 
smoking conditions were conducted within a week of 
patch application. Both studies did not find significant 
changes in fetal heart rate and umbilical artery Doppler 
examination readings. The participants in both studies 
smoked between 10 to 50 cigarettes per day during their 
pregnancy. A more recent study also enrolled 21 preg-
nant women smoking more than 15 cigarettes per day 
[23]. Participants were given 22-mg nicotine patches 
(24 hours/day) and monitored for four days in-hospital 
followed by an eight-week period outside the hospital 
setting. In all patients, non-stress tests were reactive or 
became reassuring with observation. There were also no 
significant pre-term deliveries in this study (gestational 
age ranged between 36.3 to 41.1 weeks). In all three 
studies, participants were enrolled in the third trimester, 
so results are limited to the later part of pregnancy. The 
forth, and only randomized controlled study investigat-
ing nicotine patch and pregnancy (n=250) was pub-
lished by Wisborg et al [24]. Healthy pregnant women 
less than 22 weeks pregnant, smoking more than 10 
cigarettes per day were given prenatal smoking cessa-
tion counseling by a midwife four times during the 
pregnancy and assigned either nicotine patch or pla-
cebo. Treatment duration was 11 weeks for both groups. 
In the active group, participants were given 15-mg 
patches (16 hours/day) for eight weeks followed by 10-
mg patches (16 hours/day) for three weeks. In this Dan-
ish study, the mean birth weight of the newborns was 
186g (95% CI) heavier than the control group. The in-
vestigators also found no significance in the rate of low 
birth weight (less than 2500g) and preterm babies be-
tween groups. Of the participants in the nicotine patch 
group, 26% had stopped smoking throughout the preg-
nancy and 14% remained smoked free at one-year post-
partum. Both these results were not significant to the 
control group. 
Another controlled study has also looked at the 
efficacy of nicotine patch in pregnant women [25]. Ka-
pur et al recruited pregnant women in their second tri-
mester and smoking more than 15 cigarettes per day. 
Participants were randomized to receive either nicotine 
transdermal patch or placebo patch for 12 weeks. The 
active group received 15-mg patches (18 hours/day) for 
eight weeks, followed by 10-mg patches (18 hours/day) 
for two weeks, then 5-mg (18 hours/day) for two 
Ectopic Pregnancy 40-47 
Premature Rupture of Membrane 46;48-53 
Abruptio Placentae 46;54-63 
Spontaneous Abortion 64-68 
Placenta Previa 55;69-78 
Low birthweight (<2500g)/ Small for Gestational 
Age 79-105 
Preterm Delivery (<37 weeks) 106-111 
Stillbirth 112-115 
Neonatal mortality 116;117 
Perinatal mortality 105 
SIDS 118;119 
Cognitive deficit 120-122
Table 1: Reproductive concerns that are associated with 
cigarette smoke exposure
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weeks. Researchers enrolled 30 patients before ending 
the study prematurely after one patient experienced 
severe signs of withdrawal and rapid and forceful 
movements from the fetus. These symptoms subsided 
after the patient smoked a cigarette. Fetal ultrasound, an 
obstetrical examination and a nonstress test were nor-
mal. Of the individuals participating in the study, 17 
received nicotine patch, 13 received placebo. Success 
rates between active and controller rates were not statis-
tically significant, with only three participants complet-
ing their assigned therapy in the active group and no 
participants in the control group.  
 
Nicotine Gum  
Several studies have looked at the use of nicotine 
gum in pregnant smokers. Specifically, these studies 
measured maternal nicotine levels and short-term fetal 
response to nicotine gum. One of the earliest studies in 
nicotine and fetal response [26] measured fetal breath-
ing movements in 12 pregnant women before and after 
chewing nicotine gum (Nicorette
). Seven participants 
received one piece of gum containing 4 mg nicotine, 
while the other five were given two pieces to take 
simultaneously. Nicotine levels were obtained from 
venous blood taken before nicotine gum administration, 
30 minutes and 60 minutes after the initiation of chew-
ing. There was a significant decrease in fetal breathing 
25 minutes after administration of 8 mg nicotine gum, 
but slowly recovered to non-significant levels at 35 
minutes after administration. Decreased fetal breathing 
was not significant for participants taking the 4 mg 
nicotine gum. In a separate study [27] (n=12), investi-
gators compared maternal and fetal response when par-
ticipants used 4 mg nicotine gum and when they used 
placebo gum. Participants were given a chewing gum 
combination of: one piece nicotine followed by one 
piece placebo, two nicotine gums one after the other, or 
two placebo gums. Each participant was given all three 
combinations on separate days. Maternal heart rate, 
diastolic and systolic blood pressures increase after 
nicotine gum use but not placebo gum use. Also, fetal 
heart rate, aortic blood flow and umbilical venous blood 
flow were unchanged with nicotine and placebo gum 
use. A more recent study compared nicotine gum to 
cigarette smoking in separate groups of pregnant 
women. For a five-day period, 19 participants received 
nicotine gum, while 10 continued to smoke. Individuals 
in the nicotine gum group were given a fixed dosage 
regimen of at least six pieces of gum a day but no more 
than 30 pieces per day or two pieces per hour. This 
study found no difference in maternal heart rate and 
blood pressure, fetal heart rate and umbilical artery re-
sistance [28]. Lower maternal blood nicotine levels 
were observed in gum use versus smoking, suggesting 
that in pregnant women, nicotine gum delivers less 
nicotine than cigarette smoking. All three studies only 
enrolled pregnant women in their third trimester and 
smoking more than 10 cigarettes per day. 
 
NON-NICOTINE SMOKING CESSATION 
THERAPIES AND PREGNANCY 
 
Bupropion 
Zyban (bupropion) is gaining popularity as an al-
ternative to administering nicotine for smoking cessa-
tion. Originally intended to treat depression, one of the 
side effects of bupropion was smoking cessation. Cur-
rently, bupropion is classifed as Pregnancy Category B, 
indicating a negative association with fetal harm in 
animal studies, but no well-controlled studies in human 
pregnancies. Teratology tests by the manufacturer have 
been conducted up to doses of 450 mg/kg in rats and up 
to 150mg/kg in rabbits, without impaired fertility or 
fetal harm. The manufacturer has also assembled a bu-
propion pregnancy registry to understand the safety of 
this drug during pregnancy [29]. The most recent in-
terim report, issued in December 2002, covered results 
from September 1997 to August 2002. As of August 
2002, the registry had 668 patients enrolled, with 334 
pregnancy outcomes. From the 334 pregnancy out-
comes, there were 289 live births, 32 spontaneous abor-
tions, one fetal death and 11 therapeutic abortions. 
Seven birth defects were reported from the 289 live 
births and one was reported from the therapeutic abor-
tions. The eight birth defects were specifically: one 
child with bilateral clubfeet, another child with abnor-
mal aortic valve thickening with secondary mild aortic 
insufficiency, one with ventricular septal defect, one 
with trivial valvular pulmonic stenosis, one with Kline-
felter's Syndrome but no physical abnormalities, one 
with congenital heart defect (coarctation) and ventricu-
lar septal defect, one premature infant with a thickened 
heart muscle and one induced abortion with possible 
Down Syndrome detected in prenatal test. Glaxo-
SmithKlein also receive retrospective reports of preg-
nant women using bupropion and their outcomes. From 
these reports there have been 11 cases of birth defects. 
An Advisory Committee overseeing the bupropion reg-
istry did not find a common pattern among the prospec-
tive reports of birth defects. Of the nine retrospective 
cases, there were four cardiac-related defects. However, 
whether the rate of cardiac defects is significantly high-
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er than the general population remains undetermined 
because the denominator is unknown, and because of 
the bias found in retrospective reports. Motherisk has 
an unpublished prospective, on-going study investigat-
ing the safety of bupropion use during pregnancy. Cur-
rently, there are 101 participants in the study and 97 
pregnancy outcomes thus far. Of the pregnancy out-
comes, there were 71 live births, 18 miscarriages and 
eight therapeutic abortions. There are still three preg-
nancies pending and one participant was lost to follow-
up. Of the live births, there were no reports of major 
malformations. Miscarriage rate, mean birth weight and 
gestational age at delivery were all found to be non-
significant when compared to a control group that con-
sisted of pregnant women who had contacted Mother-
isk, but were not exposed to any teratogens. 
 
THE PHARMACOKINETICS OF NICOTINE 
DURING PREGNANCY 
 
There are two studies that have looked at the 
pharmacokinetics of nicotine in pregnant women. In a 
study by Selby et al, 19 Caucasian pregnant women had 
blood nicotine and cotinine levels measured [30]. This 
study group reported an inability to stop smoking dur-
ing their pregnancy, despite understanding the risks. 
Levels of blood nicotine were lower than expected for 
the amount of cigarettes reportedly smoked. Cotinine 
levels, on the other hand, were higher than the average 
levels per cigarette in pregnant women. The results 
suggest an increase in nicotine metabolism in a sub-
group of pregnant women who cannot stop smoking. A 
separate study by Dempsey et al measured levels of 
nicotine and cotinine in 10 pregnant women after infu-
sion of deuterium labelled nicotine [31]. Women were 
given one or two 30-minute infusions during pregnancy 
and one infusion post-partum. The dose of nicotine 
given (1.0 or 1.5 micrograms/kg/min) was similar to 
smoking two cigarettes. A comparison of nicotine and 
cotinine levels during and post pregnancy revealed sig-
nificant increases in nicotine and cotinine clearance 
during pregnancy. The authors concluded that all preg-
nant women have accelerated nicotine metabolism. 
However, in this study, all participants were active 
smokers during their pregnancy. The results from this 
study may not represent the metabolism levels of envi-
ronmental nicotine in non-smokers and ex-smokers. 
Further studies are necessary to accurately determine 
whether an increase in nicotine metabolism is found in 
all pregnant women or only in pregnant women who 
can't stop smoking. These two studies were also unable 
to determine whether the observed increase in metabo-
lism is a result of a larger number of metabolism en-
zyme CYP3s, or greater hepatic clearance due to the 
pregnancy. There are still many questions surrounding 
the pharmacokinetics of nicotine during pregnancy. A 
better understanding of this area will help health au-
thorities set up proper guidelines for smoking cessation 
in pregnancy. 
 
CURRENT GUIDELINES FOR SMOKING 
CESSATION IN PREGNANCY 
 
Nicotine Replacement Therapy 
In the 2002 edition of the CPS all brands of nico-
tine gum and patch are contraindicated during preg-
nancy. The monograph for Nicotrol
, available only in 
the US, elaborated on the reasoning behind the contra-
indication, stating tobacco smoke and nicotine through 
animal studies have been shown to cause fetal harm. 
Therefore the use of this nicotine product may also 
cause damage to the human fetus.  
Most guidelines on the use of NRT and preg-
nancy, however, do not agree with such restrictions. 
The Ontario Medical Association (OMA) in literature 
published in 1999 have recommended that "NRT 
should be made available to pregnant women who are 
unable to quit using non-pharmacological methods [32]. 
Physicians should closely monitor nicotine dosage to 
ensure that nicotine levels do not exceed smoking 
levels. As with other drugs, NRT dosage should be 
matched to suit the smoker's needs." It was also rec-
ommended that "Health Canada's labelling require-
ments should be modified to include consideration of 
NRT use among pregnant women." The American 
Agency for Health Care Policy and Research (AHCPR) 
has similar recommendations for its clinical practice 
guideline [33]. It is recommended that due to the risks 
of smoking to the fetus, pregnant smokers should be 
given more rigorous psychosocial interventions (e.g. 
videos, quit packages) that go beyond typical advice to 
quit. Such smoking cessation interventions should per-
sist throughout the pregnancy to ensure abstinence. 
However if psychosocial intervention is not successful, 
pharmacotherapy is recommended as a consideration if 
the benefits of its use surpass the risks of the treatment 
and continued smoking. The Royal College of Physi-
cians has also expressed similar recommendations for 
NRT and pregnancy use in Britain [34]. Currently, both 
France and Germany permit the use of all forms of 
NRT under physician advice and supervision, provided 
non-pharmacological methods have been unsuccessful 
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[35]. The United Kingdom has made similar recom-
mendations for the nicotine gum, lozenge, patch and 
tablet. However, the nicotine spray and inhaler remain 
contraindicated in pregnancy [35]. In the publication 
titled Women and the Tobacco Epidemic: Challenges in 
the 21
st Century by the World Health Organization, 
Richard Windsor also recommends the use of NRT if 
non-pharmacological methods are unsuccessful [36]. 
Furthermore, it is suggested that five questions be con-
sidered by the physician when making the recommen-
dation of NRT to a pregnant patient:  
1. Has the patient been provided “Best Practice” 
(e.g. videos, information packages) methods yet did 
not quit? 
2. Has the patient reported smoking more than 10 
cigarettes per day? 
3. Does the patient smoke her first cigarette 
within the first 60 minutes of getting up? 
4. Has the patient indicated that she want to quit? 
5. Is the fetus’s gestational age less than 20 
weeks? 
 There has been a suggestion that the recommen-
dation to initially treat pregnant smokers with psycho-
social interventions before considering NRT may not be 
beneficial to all patients. McNeill et al, in a critique of 
current NRT practices, suggests that smoking cessation 
therapy in pregnant patients will have the greatest im-
pact if a medical professional assessed the patient's 
situation, earlier on in pregnancy, based on past quit 
attempts and smoking history [37]. A pregnant woman 
with a low probability of quitting smoking by non-
pharmacological means should not be subjected to psy-
chosocial interventions because of the risk of a failed 
quit attempt causing decreased motivation to stop and 
resulting in continual smoking during pregnancy. 
Therefore, the authors suggest the contraindication of 
NRT use in pregnancy be removed and medical profes-
sionals conduct an early assessment, suggesting NRTs 
to the pregnant mother if the probability of cessation 
without it is minimal.  
 
Bupropion 
The monograph for Zyban and Wellbutrin, men-
tion animal studies showing no association between the 
use of bupropion and fetal harm. However, since animal 
studies do not necessarily reflect human outcomes and 
because there is a lack of controlled studies, according 
to the manufacturer, bupropion should be given to a 
pregnant woman only if it is necessary. 
 
CONCLUSION 
 
There have been several studies published about 
the use of different pharmacological treatments in preg-
nant women. Currently, none of these studies have re-
vealed a serious concern with NRT or bupropion use 
during pregnancy. However, most of these studies have 
small patient numbers, focus on immediate effects of 
short term NRT use and are limited to use in the third 
trimester. Nicotine is associated with possible harm to 
the fetus so psychosocial/behavioural therapy is ideal. 
However, if non-pharmacological treatments are inef-
fective, pregnant patients with the physician’s assis-
tance should weigh the pros and cons of NRT use. On 
the one hand, NRTs contains only nicotine, eliminating 
the patient’s exposure to carbon monoxide and other 
carcinogens. As well, the plasma nicotine levels ob-
tained from NRT use is within the therapeutic range in 
pregnant women [38], and all formulations should give 
a smaller dose of nicotine than smoking [39]. On the 
other hand, the effectiveness of NRTs in pregnancy is 
still unknown and nicotine withdrawl may have serious 
consequences to the fetus. The risk to benefit ratio for 
NRT use in pregnancy is still inconclusive. However, 
NRT with close supervision by the physician can poten-
tially satisfy a pregnant woman's desire to smoke with-
out exposing the patient to nicotine levels higher than 
that obtained from smoking. Currently, research has not 
shown an association between bupropion use in preg-
nancy and fetal malformations. However, more research 
is required before any definite conclusions can be 
made. Physicians and patients should weigh the risks 
and benefits of taking this medication during preg-
nancy. 
There is a need for further studies on the safety 
and effectiveness of NRT use in pregnancy. At the 
same time, greater effort should be placed in educating 
medical professionals about smoking cessation therapy 
for pregnant women, so health care providers can offer 
the best possible treatment. With better therapy in this 
specialized group, hundreds of pregnancies with ad-
verse outcomes can be avoided. 
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